Agilent, S. Korean Hospital Ink Biomarker Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies and Seoul National University Hospital in South Korea are collaborating to develop and verify biomarkers for use in developing drugs, they announced Wednesday.

Drugs to be developed as part of the deal include narcotics and immune suppressants.

Agilent is supplying its 6460 Triple Quadrupole LC/MS system, as well as support services and application expertise to the work. The hospital will create and maintain "an optimal environment for new biomarkers to be identified and tested vigorously," the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.